<DOC>
	<DOCNO>NCT00493077</DOCNO>
	<brief_summary>This study find safety effectiveness Avonex ( interferon-beta-1a ) Therapy patient develop neutralize antibody previous interferon-beta treatment</brief_summary>
	<brief_title>Safety Avonex Treatment Multiple Sclerosis Patients With Neutralizing Antibodies Interferon Beta Therapy</brief_title>
	<detailed_description>This multi-centre , prospective , open label , non-comparative phase IV trial . Eligible patient receive treatment IFN-beta-1a AVONEX® 30 mcg i.m . weekly 12 months.The patient examine clinically NAb titre perform screen 12 month . Adverse event source verification perform documentation period .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<criteria>Relapsingremitting MS accord Poser criterion ( CDMS LSDMS ) 30 MS accord McDonald criterion Disability equivalent EDSS 6.0 less screen Neutralizing antibody titre &gt; 20 &lt; 500 two consecutive NAb test . One must screen previous treatment either subcutaneous administer interferonb1b ( Betaferon® ) interferonb1a ( Rebif TM ) prior enrolment A priori decide treated AVONEX Is NAb positive AVONEX History major depression Cardiac insufficiency , cardiomyopathy , significant cardiac dysrhythmia , unstable advanced ischemic heart disease ( NYHA III IV ) , significant hypertension ( BP &gt; 180/110 mmHg ) Renal insufficiency define serum creatinine &gt; 1.5 time upper normal reference limit Any systemic disease influence patient 's safety compliance , evaluation disability Women pregnant , breastfeed possibility pregnancy trial . To avoid pregnancy , woman postmenopausal , surgical sterile , sexually inactive practice reliable contraceptive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Neutralizing antibody</keyword>
	<keyword>Safety</keyword>
	<keyword>Low immunogenicity</keyword>
	<keyword>interferon</keyword>
	<keyword>interferon-beta-1a</keyword>
</DOC>